| BOXED WARNING:
WARNING: INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS
Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. NUPLAZID is not approved for the treatment of patients with dementia-related psychosis unrelated to the hallucinations and delusions associated with Parkinson's disease psychosis
Initial U.S. Approval: 2016
Mechanism of Action:
| INDICATIONS AND USAGE:
NUPLAZID is an atypical antipsychotic indicated for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis.
| Drug UPDATES: NUPLAZID™ (pimavanserin) tablets
[Drug information / PDF]
Package insert - Dosing: Click (+) next to Dosage and Administration section (drug info link)
DOSAGE AND ADMINISTRATION
National Institutes of Health, U.S. National Library of Medicine, DailyMed Database.
Provides access to the latest drug monographs submitted to the Food and Drug Administration (FDA). Please review the latest applicable package insert for additional information and possible updates. A local search option of this data can be found here.